Fig. 2From: Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort studyCMR-derived ECV maps before and after tafamidis treatmentCMR-derived ECV maps at baseline (top raw) and 1-year follow-up after tafamidis treatment (bottom raw)Back to article page